Aldeyra shares jump 13.79% on FDA dispute plan for reproxalap
AI Summary- Aldeyra plans to seek FDA dispute resolution over its reproxalap program.
- 13.79%: ALDX shares rose to $1.32, according to Benzinga Pro data.
- FDA issued a March Complete Response Letter on reproxalap’s New Drug Application.